A flexible, cost-effective,
targeted protein degradation platform.
Aptadegrad enables the rapid discovery of novel degraders tailored for the degradation of targeted proteins.
Rapid development of new degraders
Flexible and compatible with different molecules
Reduce costs and logistic constraints
A new way of treating diseases
Aptadegrad is a flexible, cost-effective platform developed for the discovery of novel compounds (protein degraders), based on the combination of an aptamer (as a warhead against the protein of interest) and a degrader, that harnesses protein degradation pathways within the cells.
A platform for the discovery of novel compounds
Rapid development of new degraders
The in vitro aptamers selection allows the rapid development of warheads, paving the way to address various types of diseases that currently are highly unmet clinical needs.
Flexible and compatible with different molecules
Our compounds can be tailored by a) changing the warhead to target intra-, extracellular or membrane proteins or b) by shifting the degrader tail to trigger the lysosomal or the proteasomal degradation pathway.
Reduce costs and logistic constraints
Non-biological manufacturing of both the chemical degraders and the warheads avoids high costs and greatly reduces logistics constraints.
Advantages of Targeted Protein Degradation
- The compound does not need to reach functional regions of a given target; it just needs to reach it to unleash the cell machinery to degrade the whole protein.
- Degradation induces slower kinetics, thus enabling a moderate, dose-dependent and reversible effect.
- Absence of hypersensitivity reactions (such as cytokine-release reactions).
- Low immunogenicity avoiding issues from anti-drug antibodies (ADAs) formation after repeated mAbs administration.
- Avoid undesired effects of other blocking approaches with mAbs.
Mechanism of Action
1. TPD System for specific Recognition of POI
2. Mechanisms of internalization
3. Mechanisms of Degradation
Platform building-blocks
In vitro selection of highly specific warheads against proteins in the intracellular, extracellular space or membrane proteins.
Chemical techniques for the development of small molecule protein degraders and their conjugation with the aptamers.
Cutting-edge in-vitro assays to assess the internalization, induced degradation, safety and mechanism of action of the compounds.
Advanced in-silico methodology for compound optimization.
Pipeline
Investors
We believe that our technology platform for the discovery and development of degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously undruggable with traditional modalities. The company is rapidly growing and offers a compelling business case for external investors who would be interested in widening their portfolios with a ground-breaking company in the field of targeted protein degradation.
Contact us
Partnering
Aptadegrad is eager to set up new partnerships with biotech/pharma companies to develop or co-develop novel treatments based either on aptamers/biologics or small molecules than can take advantage of our technology platform to go beyond an inhibition/blocking therapeutic approach. Should you be interested in collaborating with us please contact us.